Effect of heat stress and bezafibrate on mitochondrial β-oxidation: Comparison between cultured cells from normal and mitochondrial fatty acid oxidation disorder children using in vitro probe acylcarnitine profiling assay

Brain and Development

Volumn 32, Issue 5, 2010, Pages 362-370

  Li, Hong ^a,b   Fukuda, Seiji ^a   Hasegawa, Yuki ^a   Kobayashi, Hironori ^a   Purevsuren, Jamiyan ^a   Mushimoto, Yuichi ^a   Yamaguchi, Seiji ^a  

^a SHIMANE UNIVERSITY FACULTY OF MEDICINE   (Japan)

^b AFFILIATED HOSPITAL OF NINGXIA MEDICAL UNIVERSITY   (China)

Author keywords

Acylcarnitine profiling; Bezafibrate; Heat stress; In vitro; Mitochondrial fatty acid oxidation disorder

Indexed keywords

ACYLCARNITINE; BEZAFIBRATE; FATTY ACID; LONG CHAIN ACYL COENZYME A DEHYDROGENASE; MEDIUM CHAIN ACYL COENZYME A DEHYDROGENASE; PALMITIC ACID;

ADOLESCENT; ARTICLE; CARDIOMYOPATHY; CELL COUNT; CELL VIABILITY; CHILD; CLINICAL ARTICLE; CONTROLLED STUDY; CULTURE MEDIUM; DISORDERS OF MITOCHONDRIAL FUNCTIONS; ENZYME DEFICIENCY; FATTY ACID OXIDATION; FIBROBLAST CULTURE; HEAT STRESS; HUMAN; HUMAN CELL CULTURE; IN VITRO STUDY; LONG CHAIN ACYL COENZYME A DEHYDROGENASE DEFICIENCY; MEDIUM CHAIN ACYL COENZYME A DEHYDROGENASE DEFICIENCY; MITOCHONDRIAL FATTY ACID OXIDATION DISORDER; MITOCHONDRION; SKIN FIBROBLAST; TANDEM MASS SPECTROMETRY; TEMPERATURE;

ACYL-COA DEHYDROGENASE; ACYL-COA DEHYDROGENASE, LONG-CHAIN; ANTILIPEMIC AGENTS; BEZAFIBRATE; CARNITINE; CELLS, CULTURED; CHILD; FATTY ACIDS; FIBROBLASTS; HOT TEMPERATURE; HUMANS; LIPID METABOLISM, INBORN ERRORS; MITOCHONDRIA; MITOCHONDRIAL DISEASES; OXIDATION-REDUCTION; STRESS, PHYSIOLOGICAL;

EID: 77951022487     PISSN: 03877604     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.braindev.2009.06.001     Document Type: Article

References (32)

1. Mizuguchi M. Acute necrotizing encephalopathy of childhood: a novel form of acute encephalopathy prevalent in Japan and Taiwan. Brain Dev 1997, 19:81-92.
2. Togashi T., Matsuzono Y., Narita M., Morishima T. Influenza-associated acute encephalopathy in Japanese children in 1994-2002. Virus Res 2004, 103:75-78.
3. Yao D.B., Mizuguchi H., Yamaguchi M., Yamada H., Chida J., Shikata K., et al. Thermal instability of compound variants of carnitine palmitoyltransfers II and impaired mitochondrial fuel utilization in influenza-associated encephalopathy. Hum Mutat 2008, 29:718-727.
4. Chen Y., Mizuguchi H., Yao D.B., Ide M., Kuroda Y., Shigematsu Y., et al. Thermolabile phenotype of carnitine palmitoyltransferase II variations as a predisposing factor for influenza-associated encephalopathy. FEBS Lett 2005, 579:2040-2044.
5. Purevsuren J., Hasegawa Y., Kobayashi H., Endo M., Yamaguchi S. Urinary organic metabolite screening of children with influenza-associated encephalopathy for inborn errors of metabolism using GC/MS. Brain Dev 2008, 30:520-526.
6. Eaton S., Bartlett K., Pourfarzam M. Mammalian mitochondrial β-oxidation. Biochem J 1996, 320:345-357.
7. Rinaldo P., Matern D., Bennett M.J. Fatty acid oxidation disorders. Annu Rev Physiol 2002, 64:477-502.
8. Strauss A.W., Powell C.K., Hale D.E., Anderson M.M., Ahuja A., Brackett J.C., et al. Molecular basis of human mitochondrial very long chain acyl-CoA dehydrogenase deficiency, causing cardiomyopathy and sudden death in childhood. Proc Natl Acad Sci USA 1995, 92:10496-10500.
9. Lundemose J.B., KOlvraa S., Gregersen N., Christensen E., Gregersen M. Fatty acid oxidation disorders as primary cause of sudden and unexpected death in infants and young children: an investigation performed on cultured fibroblasts from 79 children who died aged between 0-4 years. Mol Pathol 1997, 50:212-217.
10. Wilcken B., Wiley V., Hammond J., Carpenter K. Screening newborns for inborn errors of metabolism by tandem mass spectrometry. N Engl J Med 2003, 348:2304-2312.
11. Spiekerkoetter U., Sun B., Zytkovicz T., Wanders R., Strauss A.W., Wendel U. MS/MS-based newborn and family screening detects asymptomatic patients with very long-chain acyl-CoA dehydrogenase deficiency. J Pediatr 2003, 143:335-342.
12. Ahmed R.G. Heat stress induced histopathology and pathophysiology of the central nervous system. Int J Devl Neurosci 2005, 23:549-557.
13. Pourfarzam M., Schaefer J., Turnbull D.M., Bartlett K. Analysis of fatty acid oxidation intermediates in cultured fibroblasts to detect mitochondrial oxidation disorders. Clin Chem 1994, 40:2267-2275.
14. Sim K.G., Carpenter K., Hammond J., Christodoulou J., Wilcken B. Quantitative fibroblast acylcarnitine profiles in mitochondrial fatty acid - oxidation defects: phenotype/metabolite correlations. Mol Genet Metab 2002, 76:327-334.
15. Andresen B.S., Olpin S., Poorthuis B.J.H., Scholte H.R., Vianey-Saban C., Wanders R., et al. Clear correlation of genotype with disease phenotype in very-long-chain Acyl-CoA dehydrogenase deficiency. Am J Hum Genet 1999, 64:479-494.
16. Liebig M., Schymik I., Mueller M., Wendel U., Mayatepek E., Ruiter J., et al. Neonatal screening for very long-chain acyl-CoA dehydrogenase deficiency: enzymatic and molecular evaluation of neonates with elevated C14:1-carnitine levels. Pediatrics 2006, 118:1065-1069.
17. Djouadi F., Bastin J. PPARs as therapeutic targets for correction of inborn mitochondrial fatty acid oxidation disorders. J Inher Metab Dis 2008, 31:217-225.
18. Bradford M.M. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of pretein-dye binding. Anal Biochem 1976, 72:248-254.
19. Honma Y., Ishii Y., Yamamoto-Yamaguchi Y., Sassa T., Asahi K. Cotylenin A a differentiation-inducing agent, and interferon-α cooperatively induce apoptosis and have an antitumor effect of human non-small cell lung carcinoma cells in nude mice. Cancer Res 2003, 63:3659-3666.
20. Ghisla S., Thorpe C. Acyl-CoA defydrogenases A mechanistic overview. Eur J Biochem 2004, 271:494-508.
21. Yamaguchi S. Newborn screening in Japan: restructuring for the new era. Ann Acad Med Singapore 2008;37(Suppl. 3):13-7.
22. Roe D.S., Vianey-Saban C., Sharma S., Zabot M.T., Roe C.R. Oxidation of unsaturated fatty acids by human fibroblasts with very-long-chain acyl-CoA dehydrogenase deficiency: aspects of substrate specificity and correlation with clinical phenotype. Clinica Chimica Acta 2001, 312:55-67.
23. Roe D.S., Yang B.Z., Vianey-Saban C., Struys E., Sweetman L., Roe C.R. Differentiation of long-chain fatty acid oxidation disorders using alternative precursors and acylcarnitine profiling in fibroblasts. Mol Genet Metab 2006, 87:40-47.
24. 13C] palmitic acid: an improved tool for the diagnosis of fatty acid oxidation defects. Clinica Chimica Acta 1999, 281:1-17.
25. Okun J.G., Kolker S., Schulze A., Kohlmuller D., Olgemoller K., Lindner M., et al. A method for quantitative acylcarnitine profiling in human skin fibroblasts using unlabelled palmitic acid: diagnosis of fatty acid oxidation disorders and differentiation between biochemical phenotypes of MCAD deficiency. Biochim Biophys Acta 2002, 1584:91-98.
26. Sim K.G., Hammond J., Wilcken B. Strategies for the diagnosis of mitochondrial fatty acid β-oxidation disorders. Clinica Chimica Acta 2002, 323:37-58.
27. Gobin-Limballe S., Djouadi F., Aubey F., Olpin S., Andresen B.S., Yamaguchi S., et al. Genetic basis for correction of very-long-chain acyl-coenzyme A dehydrogenase deficiency by bezafibrate in patient fibroblasts: toward a genotype-based therapy. Am J Hum Genet 2007, 81:1133-1143.
28. Scholte H.R., Van Coster R.N.A., Jonge P.C., Poorthuis B.J.H.M., Jeneson J.A.L., Andresen B.S., et al. Myopathy in very-long-chain acyl-CoA dehydrogenase deficiency: clinical and biochemical differences with the fatal cardiac phenotype. Neuromuscul Disord 1999, 9:313-319.
29. Barish G.D., Narkar V.A., Evans R.M. PPAR delta: a dagger in the heart of the metabolic syndrome. J Clin Invest 2006, 116:590-597.
30. Djouadi F., Aubey F., Schlemmer D., Gobin S., Laforet P., Wanders R.J.A., et al. Potential of fibrates in the treatment of fatty acid oxidation disorders: revival of classical drugs?. J Inherit Metab Dis 2006, 29:341-342.
31. Djouadi F., Bonnefont J.P., Thuillier L., Droin V., Khadom N., Munnich A., et al. Correction of fatty acid oxidation in carnitine palmitoyl transferase 2-deficient cultured skin fibroblasts by bezafibrate. Pediatric Res 2003, 54:446-451.
32. Djouadi F., Aubey F., Schlemmer D., Ruiter J.P.N., Wanders R.J.A., Strauss A.W., et al. Bezafibrate increases very-long-chain acyl-CoA dehydrogenase protein and mRNA expression in deficient fibroblasts and is a potential therapy for fatty acid oxidation disorders. Hum Mol Genet 2005, 14:2695-2703.